Overall, the expression of NK maturation markers CD16, CD57 and killer-cell immunoglobulin-like receptors on CD56dim NK cells in the tumour-draining lymph nodes [67,92,93] suggests that highly cytotoxic NK cells are present in the lymph nodes of cancer patients and that they may be an attractive target for therapeutic strategies. This evidence concerns the gene B3GAT1 and cancer.